A quick analysis of Celgene Corporation (NASDAQ: CELG) stock history reveals three distinct stages with four stock splits along the way. These stages led to the company becoming what the following chart shows it to be -- one of the …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
At $95.64, the stock has room to fall short-term, even if the positive trends remain in place: “Correction support” comes into play at the $89.70-$91.30 range and the long-term uptrend line comes into play at around $83. Technicians still call …
Biotech funds have rallied to multi-month highs, but bearish price action in sector giants Celgene Corp. (CELG ... range that’s contained price action for the last year. The stock posted lower highs in October and December, ahead of a test …
Celgene Corporation CELG is scheduled to report first-quarter 2016 results on Apr 28, before the market opens. Last quarter, the company reported a negative earnings surprise of 1.96%. Let's see how things are shaping up for this …
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that its stockholders approved a two-for-one stock split and an increase from 575 million to 1,150 million in the number of authorized shares …
Key highlights this week include the announcement of a couple of acquisition agreements as well as pipeline news from Biogen BIIB and Celgene CELG. The M&A announcements relate to the acquisition of Ignyta RXDX by Roche and …
Hyderabad: Natco Pharma Ltd and partner Allergan Plc on Wednesday reached a settlement with US-based drug maker Celgene Corp. in the patent infringement ... pharma expert at Karvy Stock Broking Ltd. “The entry of a new potent drug …